Joseph Schwartz's questions to Crinetics Pharmaceuticals (CRNX) leadership • Q2 2025
Question
Joseph Schwartz of Leerink Partners inquired about the potential impact of Neurocrine's Crinesity launch on the enrollment pace for Crinetics' Phase III studies in congenital adrenal hyperplasia (CAH) and whether it selects for specific patient types.
Answer
Founder and CEO R. Scott Struthers responded that he views the Crinesity launch as a positive development that raises disease awareness and should actually benefit enrollment, noting that the bulk of Crinetics' trial enrollment is outside the U.S. Chief Medical & Development Officer Dana Pizzuti added that Crinetics is targeting a broader CAH patient population, aiming to address the full spectrum of the disease, which is a key distinction.